Cronos Group Inc. (CRON) - Stock Analysis

Last updated: Jun 7, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Cronos Group shows record revenue and profitability growth, an accretive European acquisition, strong liquidity, and a 33% 3-week stock surge breaking resistance, backed by favorable regulatory outlook and cannabis sector tailwinds, making it a highly attractive short-term growth idea.

Loading chart data...

Idea window: 12/15/2025 – 12/22/2025Sector: Healthcare

AI Analyst Overview

Last Price
$2.68
Market Cap
$1.04B
1D Return
-2.55%
YTD Return
+1.90%

Loading chart data...

Valuation Metrics

P/E
-111.4
P/B
1.0
P/S
7.0
EV/EBITDA
32.0
Div Yield
—

Fundamental Analysis

7.0

Key Financial Insights: • Cash Fortress • Profit Rebound • Sales Multiple CRON looks financially solid with cash-rich, near-debt-free liquidity and improving Q1 profitability, but its full-year earnings base remains unproven and valuation is still rich on sales.

Liquidity
Turnaround

Price Behavior

6.0

Key Price Behavior Insights: • Higher lows • Resistance cap • Support hold Support Level: $2.70-$2.73 Resistance Level: $2.82-$2.84 Over the last month, CRON has inched higher and remains constructive above $2.70, but repeated failures near $2.82-$2.84 show resistance is still capping the move.

constructive
watchlist

Sentiment & News

7.0

Key News Insights: • Record Revenue • Market Share Gains • International Expansion CRON's Q1 showed record revenue and gross profit, with market-share gains and international expansion reinforcing a positive growth outlook.

CRON
Cannabis
AI

AI Summary

6.0
Neutral

CRON has moved from a “survival” balance-sheet story to a real turnaround candidate, but the investment now hinges on whether record revenue and strong cash flow can be converted into sustained operating profits rather than one-off net income gains, making execution—not solvency—the key risk to monitor.

Turnaround
ExecutionRisk
BalanceSheet
AI summary updated 6 days ago

Description

Cronos Group Inc. is a Toronto-based cannabinoid company that develops, manufactures and sells hemp-derived supplements and cosmetics through e-commerce, retail and hospitality partners under the Lord Jones and Happy Dance brands. The company also cultivates and produces cannabis for medical and adult-use markets, marketing a range of consumer products through wholesale and direct channels via its PEACE NATURALS wellness platform and adult-use brands such as Spinach, and exports cannabis goods to Germany, Israel and Australia. Founded in 2012, Cronos operates across both domestic and international markets.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Dec 15Dec 22CRONCronos Group Inc.
Cronos Group shows record revenue and profitability growth, an accretive European acquisition, strong liquidity, and a 33% 3-week stock surge breaking resistance, backed by favorable regulatory outlook and cannabis sector tailwinds, making it a highly attractive short-term growth idea.
Closed-8.8%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.